A Case of Severe Pneumocystis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib
10.11106/ijt.2019.12.2.127
- Author:
Mei Hua JIN
1
;
Won Gu KIM
;
Tae Yong KIM
;
Won Bae KIM
;
Young Kee SHONG
;
Min Ji JEON
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. mj080332@gmail.com
- Publication Type:Case Report
- Keywords:
Lenvatinib;
Pneumocystis pneumonia;
Interstitial pneumonia;
Thyroid cancer
- MeSH:
Aged;
Diarrhea;
Fatigue;
Female;
Follow-Up Studies;
Humans;
Hypertension;
Lung Diseases, Interstitial;
Pneumocystis;
Pneumonia;
Pneumonia, Pneumocystis;
Protein-Tyrosine Kinases;
Proteinuria;
Thorax;
Thyroid Gland;
Thyroid Neoplasms
- From:International Journal of Thyroidology
2019;12(2):127-131
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131–refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date, no report on Pneumocystis pneumonia (PCP) in patients receiving lenvatinib has been published. Here, we present a case of severe PCP that led to the death of a 79-year-old woman who was diagnosed with poorly differentiated thyroid cancer and received lenvatinib. The development of PCP should be considered when patients taking lenvatinib show clinical symptoms of pneumonia, and regular chest X-ray follow-up is needed for patients receiving lenvatinib.
